Aclaris Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $64.9 million for 2025, while advancing its immuno-inflammatory disease pipeline and seeking third-party partnerships.
NASDAQ
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announces its 2024 financial results and highlights its focus on developing novel treatments for immuno-inflammatory diseases.
NASDAQ
10-K: Aclaris Therapeutics Outlines Capital Stock Structure and Regulatory Compliance in 10-K Filing
Aclaris Therapeutics' 10-K filing details the company's capital stock, voting rights, anti-takeover provisions, and regulatory compliance, providing a comprehensive overview of its corporate structure and operational framework.